“Identification of novel autoantibody signatures related to non-motor symptoms in individuals with high-risk of Parkinson’s Disease, using KREX-based functional protein microarrays. A cross-sectional study.”
Autoantibody biomarkers identified and validated using Sengenics protein arrays have shown utility in a range of high-value applications—from early disease detection and patient stratification to treatment monitoring and prediction of treatment outcomes and immune-related adverse events (irAE).
Learn more about key applications for Sengenics technology and services.
Biomarker Discovery and Validation
Identification of autoantibody biomarker
signatures.
Patient Stratification
Intra-disease stratification, identification of cohorts and clinical trial patient enrichment.
Response Prediction
Predict responders, non-responders and those at risk of adverse events.
Diagnostics and CDx Development
Establish biomarker signatures for companion diagnostic development.
"*" indicates required fields
